Literature DB >> 16730715

p38-MAP kinase activation followed by BIM induction is essential for glucocorticoid-induced apoptosis in lymphoblastic leukemia cells.

Jianghua Lu1, Bonnie Quearry, Hisashi Harada.   

Abstract

Glucocorticoids (GC) are common components in chemotherapeutic protocols for lymphoid malignancies. GC-induced apoptosis requires the intrinsic, BCL-2 family-regulated pathway. Treatment of CCRF-CEM (T cell acute lymphoblastic leukemia) cells with the GC, dexamethasone (Dex), activates p38-mitogen activated protein kinase (p38-MAPK) and then induces mRNA transcription and synthesis levels of BIM, a BH3-only pro-apoptotic BCL-2 family member. Dex-induced apoptosis is dramatically inhibited by downregulation of BIM by shRNA or by pretreatment with a p38-MAPK inhibitor, SB203580, which also reduces BIM induction. These findings indicate that BIM induction through p38-MAPK activation is a critical pathway in GC-induced cell death.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16730715     DOI: 10.1016/j.febslet.2006.05.031

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  41 in total

1.  Hydrogen peroxide signaling is required for glucocorticoid-induced apoptosis in lymphoma cells.

Authors:  Margaret E Tome; Melba C Jaramillo; Margaret M Briehl
Journal:  Free Radic Biol Med       Date:  2011-09-10       Impact factor: 7.376

2.  CEBPD reverses RB/E2F1-mediated gene repression and participates in HMDB-induced apoptosis of cancer cells.

Authors:  Yen-Chun Pan; Chien-Feng Li; Chiung-Yuan Ko; Min-Hsiung Pan; Pei-Jung Chen; Joseph T Tseng; Wen-Chun Wu; Wen-Chang Chang; A-Mei Huang; Esta Sterneck; Ju-Ming Wang
Journal:  Clin Cancer Res       Date:  2010-10-22       Impact factor: 12.531

3.  MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies.

Authors:  Ronit Vogt Sionov
Journal:  ISRN Hematol       Date:  2013-01-29

4.  Bim gene dosage is critical in modulating nephron progenitor survival in the absence of microRNAs during kidney development.

Authors:  Débora M Cerqueira; Andrew J Bodnar; Yu Leng Phua; Rachel Freer; Shelby L Hemker; Loren D Walensky; Neil A Hukriede; Jacqueline Ho
Journal:  FASEB J       Date:  2017-04-26       Impact factor: 5.191

5.  Preclinical In Vitro, In Vivo, and Pharmacokinetic Evaluations of FLLL12 for the Prevention and Treatment of Head and Neck Cancers.

Authors:  Abu Syed Md Anisuzzaman; Abedul Haque; Mohammad Aminur Rahman; Dongsheng Wang; James R Fuchs; Selwyn Hurwitz; Yuan Liu; Gabriel Sica; Fadlo R Khuri; Zhuo Georgia Chen; Dong M Shin; A R M Ruhul Amin
Journal:  Cancer Prev Res (Phila)       Date:  2015-10-28

6.  p38α Signaling Induces Anoikis and Lumen Formation During Mammary Morphogenesis.

Authors:  Huei-Chi Wen; Alvaro Avivar-Valderas; Maria Soledad Sosa; Nomeda Girnius; Eduardo F Farias; Roger J Davis; Julio A Aguirre-Ghiso
Journal:  Sci Signal       Date:  2011-05-24       Impact factor: 8.192

7.  MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.

Authors:  Tri K Nguyen; Mohamed Rahmani; Hisashi Harada; Paul Dent; Steven Grant
Journal:  Blood       Date:  2007-01-11       Impact factor: 22.113

8.  The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity.

Authors:  Y-H Ahn; S-O Hong; J H Kim; K H Noh; K-H Song; Y-H Lee; J-H Jeon; D-W Kim; J H Seo; T W Kim
Journal:  Clin Exp Immunol       Date:  2015-05-17       Impact factor: 4.330

9.  Activation of the AMP-activated protein kinase-p38 MAP kinase pathway mediates apoptosis induced by conjugated linoleic acid in p53-mutant mouse mammary tumor cells.

Authors:  Yung-Chung Hsu; Xiaojing Meng; Lihui Ou; Margot M Ip
Journal:  Cell Signal       Date:  2009-11-20       Impact factor: 4.315

10.  MEK inhibitors potentiate dexamethasone lethality in acute lymphoblastic leukemia cells through the pro-apoptotic molecule BIM.

Authors:  A A Rambal; Z L G Panaguiton; L Kramer; S Grant; H Harada
Journal:  Leukemia       Date:  2009-04-30       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.